The latest price target for Amphastar Pharma (NASDAQ:AMPH) was reported by Piper Sandler on August 8, 2024. The analyst firm set a price target for $66.00 expecting AMPH to rise to within 12 months (a possible 49.69% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Amphastar Pharma (NASDAQ:AMPH) was provided by Piper Sandler, and Amphastar Pharma maintained their overweight rating.

The last upgrade for Amphastar Pharmaceuticals Inc happened on January 7, 2022 when Piper Sandler raised their price target to $28. Piper Sandler previously had a neutral for Amphastar Pharmaceuticals Inc.

There is no last downgrade for Amphastar Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a maintained with a price target of $71.00 to $66.00. The current price Amphastar Pharma (AMPH) is trading at is $44.09, which is out of the analyst’s predicted range.